Skip to main content
main-content
Top

The DEFINE-HF trial

DEFINE-HF is a randomized, placebo-controlled trial testing the effects of 12 weeks of treatment with the SGLT2 inhibitor dapagliflozin in patients who have chronic heart failure with reduced systolic function, but do not necessarily have type 2 diabetes.

DEFINE-HF results published: Further support for add-on dapagliflozin as a treatment option for heart failure


Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

Read the interview transcript

The DEFINE-HF investigators reported the effects of treatment on heart failure-specific biomarkers, symptoms, and functional status at the 55th EASD Annual Meeting (EASD 2019):

Dapagliflozin effects on biomarkers, symptoms and functional status in patients with heart failure and reduced ejection fraction with and or without diabetes: the DEFINE-HF trial 
Wednesday, September 17, 13:15–14:15. Vilanova Hall, Fira Barcelona Gran Via, Spain 
Session Chair: L. Rydén, Sweden

  1. Background and rationale for DEFINE-HF trial. M. N. Kosiborod, USA
  2. DEFINE-HF study design and baseline characteristics. M. E. Nassif, USA
  3. Effect of dapagaliflozin on the primary outcomes. M. N. Kosiborod, USA
  4. Effect of dapagliflozin on secondary and safety outcomes. M. E. Nassif, USA
  5. Putting DEFINE-HF in perspective: clinical implications and path forward. M. N. Kosiborod, USA


What our Editorial Board said:

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with chronic heart failure plus reduced systolic function.



Whilst we are waiting for the results of big outcome trials with SGLT2 inhibitors in people with heart failure with and without diabetes, this smaller but important trial may give some useful information about mechanisms and other potential benefits.


John Wilding, Professor of Medicine, UK

Back to the EASD 2019 conference hub